Publication of year-end report for the fiscal year 2023/2024
News
We're thrilled to share the latest developments from our company.
- 25. Juni
- 2 Min.
ODI Pharma AB announces strategic market entry with initial shipment to Switzerland
- 30. Mai
- 4 Min.
ODI Pharma AB: Publication of interim report Q3 2023/2024
- 2. Mai
- 2 Min.
Preliminary results for ODI Pharma indicate significant revenue increase in Q3 2023/2024
- 27. Feb.
- 2 Min.
ODI Pharma AB: Updated market and business overview
- 22. Feb.
- 3 Min.
ODI Pharma AB: Publication of half-year report 2023/2024
- 18. Jan.
- 1 Min.
ODI Pharma AB anlitar Pareto Securities AB som likviditetsgarant
- 18. Jan.
- 2 Min.
ODI Pharma AB appoints Pareto Securities AB as liquidity provider
- 15. Dez. 2023
- 2 Min.
Announcement from the Annual General Meeting in ODI Pharma AB (publ)
- 15. Dez. 2023
- 2 Min.
Kommuniké från årsstämma i ODI Pharma AB (publ)
- 6. Dez. 2023
- 3 Min.
ODI Pharma AB announces sale of the skincare brand kandol. for 3.2 msek
- 27. Nov. 2023
- 2 Min.
Correction: ODI Pharma AB publishes the annual report for the fiscal year 2022/2023
- 27. Nov. 2023
- 2 Min.
Rättelse: ODI Pharma AB publicerar årsredovisning för räkenskapsåret 2022/2023
- 24. Nov. 2023
- 3 Min.
ODI Pharma AB: Publication of interim report report Q1 2023/2024
- 24. Nov. 2023
- 1 Min.
ODI Pharma AB publishes the annual report for the fiscal year 2022/2023
- 24. Nov. 2023
- 1 Min.
ODI Pharma AB publicerar årsredovisning för räkenskapsåret 2022/2023
- 23. Nov. 2023
- 1 Min.
ODI Pharma AB postpones publication of interim report and annual report until November 24, 2023
- 13. Nov. 2023
- 5 Min.
Notice to Annual General Meeting in ODI Pharma AB (publ)
- 13. Nov. 2023
- 4 Min.
Kallelse till årsstämma i ODI Pharma AB (publ)
- 24. Aug. 2023
- 4 Min.
ODI Pharma AB: Publication of year-end report for the fiscal year 2022/2023